

**NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Pimecrolimus. [Updated 2019 Oct 23].


Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



### **Pimecrolimus**

Revised: October 23, 2019.

CASRN: 137071-32-0



# **Drug Levels and Effects**

## **Summary of Use during Lactation**

Topical pimecrolimus has not been studied during breastfeeding; however, it is used topically in children as young as 3 months of age. Because it is poorly absorbed after topical application and plasma concentrations after topical use in adults are less than 2 mcg/L, it is a low risk to the nursing infant. Ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Older recommendations state that if the breast is to be treated, an alternate drug is preferred; do not apply to the nipple area while nursing.[1] [2] A newer European guideline allows pimecrolimus to be applied just after nursing, with the nipples cleaned gently and carefully before nursing.[3] Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.[4]

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

### **Alternate Drugs to Consider**

**Tacrolimus** 

#### References

- 1. Barrett ME, Heller MM, Fullerton Stone H, Murase JE. Dermatoses of the breast in lactation. Dermatol Ther. 2013;26:331–6. PubMed PMID: 23914890.
- 2. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II Lactation. J Am Acad Dermatol. 2014;70:417.e1–417.e10. PubMed PMID: 24528912.
- 3. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: Treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33:1644–59. PubMed PMID: 31231864.
- 4. Noti A, Grob K, Biedermann M, et al. Exposure of babies to C(15)-C(45) mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003;38:317–25. PubMed PMID: 14623482.

## **Substance Identification**

#### **Substance Name**

Pimecrolimus

### **CAS Registry Number**

137071-32-0

### **Drug Class**

**Breast Feeding** 

Lactation

Anti-Inflammatory Agents, Non-Steroidal

**Dermatologic Agents** 

Immunosuppressive Agents